Otilimab clinical trials
Also written GSK3196165 and MOR103.
How each study uses Otilimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 3 |
| 2020 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Studies
Open first, then newest update. How each study uses Otilimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related DiseaseCompletedPhase 2GlaxoSmithKlineNCT04376684Written as Otilimab
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to MethotrexateCompletedPhase 3GlaxoSmithKlineNCT03980483Written as GSK3196165 (Otilimab)
- Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)TerminatedPhase 3GlaxoSmithKlineNCT04333147Written as Otilimab (GSK3196165)
- Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)TerminatedPhase 3GlaxoSmithKlineNCT03970837Written as GSK3196165 (Otilimab)
- Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) InhibitorsCompletedPhase 3GlaxoSmithKlineNCT04134728Written as GSK3196165 (Otilimab)
- A Study in Healthy Japanese Participants to Evaluate the Safety and Pharmacokinetics of OtilimabWithdrawnPhase 1GlaxoSmithKlineNCT05304130Written as Otilimab
- Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid ArthritisCompletedPhase 2GlaxoSmithKlineNCT02799472Written as GSK3196165
- A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand OsteoarthritisCompletedPhase 2GlaxoSmithKlineNCT02683785Written as GSK3196165
- Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid ArthritisCompletedPhase 2GlaxoSmithKlineNCT02504671Written as GSK3196165
- Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid ArthritisCompletedPhase 1/2GlaxoSmithKlineNCT03028467Written as GSK3196165 Dose 1
- Phase Ib Study to Evaluate MOR103 in Multiple SclerosisCompletedPhase 1/2MorphoSys AGNCT01517282Written as MOR103
- Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid ArthritisCompletedPhase 1/2MorphoSys AGNCT01023256Written as MOR103
Codes
What other systems call Otilimab · ClinicalTrials.gg INT000272
- MeSH (NLM) C000599766OtilimabOne source NLM
- UNII (FDA) Y8127R3VCHOTILIMABConfirmed FDA, NLM, Wikidata
- Wikidata Q56291893otilimabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C170271OtilimabOne source FDA
- DrugBank DB06303One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000599766 | Otilimab | One source NLM |
| UNII (FDA) | Y8127R3VCH | OTILIMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q56291893 | otilimab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C170271 | Otilimab | One source FDA |
| DrugBank | DB06303 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.